Equity Profile

TWST

TWIST BIOSCIENCE COR

Health CareBiotechnology$4.3B

Aug3Mon

Pre-Earnings Brief

UpcomingQ3-2026Pre-Market9:00 AM EDT

Company Snapshot

Twist Bioscience Corporation operates in the biotechnology sector, focusing on synthetic DNA production. Their technology is crucial for various applications, including pharmaceuticals and diagnostics, making them a key player in the health care industry.

Key Metrics to Watch

Revenue Growth

Revenue growth is critical to assess the company's market demand and operational efficiency.

N/A

Earnings Per Share (EPS)

EPS provides insight into the company's profitability and is a key indicator for investors.

-$0.54

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2-2026, Twist Bioscience reported an EPS of -$0.71, which was worse than the expected -$0.54. The stock reacted negatively, dropping nearly 7% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent performance and lack of guidance. The market is watching closely for any signs of improvement in revenue and cost management.

Bull Case

If Twist can demonstrate significant revenue growth and improved margins, it may restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss EPS expectations and fails to provide a clear path to profitability, it could further depress the stock price.

Key Metrics to Watch

Revenue Growth

N/A

Revenue growth is critical to assess the company's market demand and operational efficiency.

Earnings Per Share (EPS)

-$0.54

EPS provides insight into the company's profitability and is a key indicator for investors.

Gross Margin

N/A

Gross margin indicates the efficiency of production and pricing strategy, which is vital for future profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's ability to recover from recent losses and attract investor confidence.

How is the company addressing its cost structure to improve margins?

Improving margins is essential for long-term profitability and will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in revenue growth, as recent insider selling does not necessarily reflect the company's long-term prospects.

Supporting Evidence

Despite recent losses, the company has innovative technology that could drive future growth.

The options market suggests a high level of uncertainty, indicating that investors may be overly cautious.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether the company can turn around its recent poor financial results.

Bull Confirmed If

Achieving an EPS of -$0.50 or better would signal improved operational efficiency.

Bear Confirmed If

An EPS worse than -$0.71 would confirm ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±40.05%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings outcome.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.6% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

19,268 sh

2 insiders

Net

$1.2M

Net selling

Most Active Insiders· 6 open-market trades

Chief Executive OfficerLeproust Emily M.
$630,957.35

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations, history suggests a potential stock increase of around +0.91%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of approximately -6.11%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue.
2Details on cost-cutting measures and their expected impact on margins.
3Management's outlook on market demand for synthetic DNA.
4Responses to how recent insider selling might affect investor confidence.
5Any commentary on competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Key Metrics to Watch

Revenue Growth

Revenue growth is critical to assess the company's market demand and operational efficiency.

N/A

Earnings Per Share (EPS)

EPS provides insight into the company's profitability and is a key indicator for investors.

-$0.54

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2-2026, Twist Bioscience reported an EPS of -$0.71, which was worse than the expected -$0.54. The stock reacted negatively, dropping nearly 7% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Twist can demonstrate significant revenue growth and improved margins, it may restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss EPS expectations and fails to provide a clear path to profitability, it could further depress the stock price.

Key Metrics to Watch

Revenue Growth

N/A

Revenue growth is critical to assess the company's market demand and operational efficiency.

Earnings Per Share (EPS)

-$0.54

EPS provides insight into the company's profitability and is a key indicator for investors.

Gross Margin

N/A

Gross margin indicates the efficiency of production and pricing strategy, which is vital for future profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's ability to recover from recent losses and attract investor confidence.

How is the company addressing its cost structure to improve margins?

Improving margins is essential for long-term profitability and will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in revenue growth, as recent insider selling does not necessarily reflect the company's long-term prospects.

Supporting Evidence

Despite recent losses, the company has innovative technology that could drive future growth.

The options market suggests a high level of uncertainty, indicating that investors may be overly cautious.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether the company can turn around its recent poor financial results.

Bull Confirmed If

Achieving an EPS of -$0.50 or better would signal improved operational efficiency.

Bear Confirmed If

An EPS worse than -$0.71 would confirm ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±40.05%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings outcome.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

19,268 sh

2 insiders

Net

$1.2M

Net selling

Most Active Insiders· 6 open-market trades

Chief Executive OfficerLeproust Emily M.
$630,957.35

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations, history suggests a potential stock increase of around +0.91%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of approximately -6.11%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue.
2Details on cost-cutting measures and their expected impact on margins.
3Management's outlook on market demand for synthetic DNA.
4Responses to how recent insider selling might affect investor confidence.
5Any commentary on competitive positioning in the biotechnology sector.